Clinical Trial: A Prospective, Multicenter, Single-Arm Clinical Study of Elranatamab as Bridging Therapy to BCMA CAR-T in Patients with Second-Line Multiple Myeloma (China)

China, Sept. 23 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Prospective, Multicenter, Single-Arm Clinical Study of Elranatamab as Bridging Therapy to BCMA CAR-T in Patients with Second-Line Multiple Myeloma'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133105

Registration Time: 2026/09/22

Type: Interventional study

Primary Sponsor: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=336510

Published by HT Digital Content Services with permission from Health Daily Digest....